Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)

Open access
Van Tassell, Benjamin W., Canada, Justin, Carbone, Salvatore, Trankle, Cory, Buckley, Leo, Oddi Erdle, Claudia, Abouzaki, Nayef A., Dixon, Dave, Kadariya, Dinesh, Christopher, Sanah, Schatz, Aaron, Regan, Jessica, Viscusi, Michele, Del Buono, Marco, Melchior, Ryan, Mankad, Pranav, Lu, Juan, Sculthorpe, Robin, Biondi-Zoccai, Giuseppe, Lesnefsky, Edward, Arena, Ross, Abbate, Antonio · 2017 · Circulation: Heart Failure

Abstract

Background: An enhanced inflammatory response predicts worse outcomes in heart failure (HF). We hypothesized that administration of IL-1 (interleukin-1) receptor antagonist (anakinra) could inhibit the inflammatory response and improve peak aerobic exercise capacity in patients with recently decompensated systolic HF. Methods and Results: We randomly assigned 60 patients with reduced left ventricular ejection fraction (<50%) and elevated C-reactive protein levels (>2 mg/L), within 14 days of hospital discharge, to daily subcutaneous injections with anakinra 100 mg for 2 weeks, 12 weeks, or placebo. Patients underwent measurement of peak oxygen consumption (V o 2 [mL/kg per minute]) and ventilatory efficiency (the VE/V co 2 slope). Treatment with anakinra did not affect peak V o 2 or VE/V co 2 slope at 2 weeks. At 12 weeks, patients continued on anakinra showed an improvement in peak V o 2 from 14.5 (10.5–16.6) mL/kg per minute to 16.1 (13.2–18.6) mL/kg per minute ( P =0.009 for within-group changes), whereas no significant changes occurred within the anakinra 2-week or placebo groups. The between-groups differences, however, were not statistically significant. The incidence of death or rehospitalization for HF at 24 weeks was 6%, 31%, and 30%, in the anakinra 12-week, anakinra 2-week, and placebo groups, respectively (log-rank test P =0.10). Conclusions: No change in peak V o 2 occurred at 2 weeks in patients with recently decompensated systolic HF treated with anakinra, whereas an improvement was seen in those patients in whom anakinra was continued for 12 weeks. Additional larger studies are needed to validate the effects of prolonged anakinra on peak V o 2 and rehospitalization for HF. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01936909.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circheartfailure.117.004373

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 245

Metadata

Authors
Van Tassell, B. W., Canada, J., Carbone, S., Trankle, C., Buckley, L., Oddi Erdle, C., Abouzaki, N. A., Dixon, D., Kadariya, D., Christopher, S., Schatz, A., Regan, J., Viscusi, M., Del Buono, M., Melchior, R., Mankad, P., Lu, J., Sculthorpe, R., Biondi-Zoccai, G., Lesnefsky, E., Arena, R., & Abbate, A.
Venue
Circulation: Heart Failure
Published
2017-11
Volume
10
Issue
11
ISSN
  • 1941-3289 (ISSN-L)
  • 1941-3297
OpenAlex
W2770646430
Cited by
245
References
8
FWCI
14.68
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). https://app.cochat.ai/papers/10.1161/circheartfailure.117.004373
The paper
Van Tassell, B. W., Canada, J., Carbone, S., Trankle, C., Buckley, L., Oddi Erdle, C., Abouzaki, N. A., Dixon, D., Kadariya, D., Christopher, S., Schatz, A., Regan, J., Viscusi, M., Del Buono, M., Melchior, R., Mankad, P., Lu, J., Sculthorpe, R., Biondi-Zoccai, G., . . . Abbate, A. (2017). Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circulation: Heart Failure. https://doi.org/10.1161/circheartfailure.117.004373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.